Outset Medical delivered its strongest growth quarter of 2026. Revenue of $33.6 million rose 14.2% year over year and topped the $31.5 million consensus by 6.7%. The adjusted loss of $0.77 per share beat the -$0.84 consensus by 8.3%, and earnings improved 21.4% from a year ago. The trajectory is the real story: revenue growth went from -6% in the first quarter to +1% in the second to +14% now. Every major line contributed. Console revenue rose 26% to $10.5 million, recurring revenue grew 10% to $23.1 million after shrinking 2% in Q2, and consumables swung from a 12% decline to 8% growth. That is the reacceleration turnaround skeptics were not positioned for. The central tension is that gross margin kept sliding and management declined to raise full-year guidance despite the beat.

The quality of the earnings beat deserves scrutiny. Earnings Whispers' normalized loss of $0.77 sits between the release's GAAP loss of $0.78 per share and its non-GAAP loss of $0.68. The GAAP net loss narrowed to $14.7 million from $17.8 million, but much of that improvement came from stock-based compensation falling to $1.7 million from $5.1 million. On a non-GAAP basis, the net loss actually widened slightly to $12.9 million from $12.4 million. Non-GAAP operating expenses rose to $24.2 million from $22.1 million a year earlier, although they fell sequentially from $25.8 million in Q2. Management said expenses excluding roughly $1 million of bad debt rose only 4%, well below 14% revenue growth. Lower interest income also weighed on the bottom line as the cash pile shrank.

Margins are where bears have legitimate ammunition. Headline GAAP gross margin of 40.7% was up 130 basis points year over year, but that comparison flatters the trend. Non-GAAP gross margin has fallen each quarter, from 43.8% in Q1 to 42.2% in Q2 to 40.8% in Q3. Product gross margin dropped to 44.2%, down from 45.7% a year ago and 52.4% in Q1, as lower-margin console placements made up a larger share of sales. Service margin was the bright spot, jumping 760 basis points to 32.4%. Management reiterated its low-to-mid-40% full-year non-GAAP gross margin outlook but pointed toward the lower end. In short, the growth that is reaccelerating is the least profitable kind in the near term, even if consoles seed future consumable revenue.

Management's tone on the call was noticeably more confident, centered on execution and a market opportunity it described as never more compelling. The catalysts are tangible:

• **HCA follow-through.** The refresh pipeline is building after Q2's $40 million HCA deal, and other large health systems are in refresh discussions.
• **Major health-system footprint.** Tablo is being implemented at four of the top 10 U.S. health systems, and cumulative parent-customer retention stands at 96%.
• **EMR growth.** Sales of the EMR offering rose 23%.
• **Sales overhaul.** A reworked commercial model under a new EVP introduced smaller territories, realigned compensation and an expanded national-accounts team.
• **Policy tailwind.** The new HHS Kidney Care National Plan emphasizes home dialysis and new technologies.

The offsets are equally concrete. The next-generation system, originally slated for full launch by the end of Q2, remains in pre-full release, with management stressing quality over speed. Reiterating the $125–130 million revenue range implies Q4 revenue of roughly $32–37 million, so the low end would mean a sequential decline from Q3. Full-year cash use guidance edged up to approximately $40 million from less than $40 million. Cash stands at $140.7 million against a $98.4 million term loan.

Investor sentiment improved meaningfully into the report, rising from -0.21 to -0.03, though it remains slightly negative. Price action has been volatile. Shares hit $5.28 shortly after the August report, then collapsed to a 52-week low of $2.84 on September 28. They have since rallied 46% to $4.15, almost exactly on the 200-day moving average and still 13.5% below the post-report opening price of $4.80. Momentum and AVWAP trend readings are positive while price trend is neutral, consistent with a stock recovering ground but not yet re-established.

The bottom line is that Outset answered the most pressing question, whether growth could return, with a broad-based and convincing reacceleration. The quarter also exposed the cost of that growth. Gross margin is drifting lower, the non-GAAP loss did not improve, and management chose not to raise its outlook. With the stock parked at its 200-day average after a sharp rebound, the next leg likely depends on whether Q4 sustains this revenue pace and whether the next-generation launch and refresh pipeline can halt the margin slide.